KnitWell Group Supports the Breast Cancer Research Foundation With Eight Iconic American Retail Fashion Brands Through Their Sisterhood of Strength Campaign
September 18, 2024 15:25 ET | D S Simon
NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- In honor of Breast Cancer Awareness Month, a leading multi-brand retail operating company, KnitWell Group, comprised of Ann Taylor, Chico’s, Haven Well...
plus_logo.png
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
September 18, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
logo.jpg
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
September 18, 2024 05:00 ET | ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
Wistar Institute Res
Wistar Institute Researchers Identify Parkinson-related Protein’s Role in Cancer and T Cell Activation
September 17, 2024 12:54 ET | The Wistar Institute
PHILADELPHIA, PA, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Wistar Institute’s President and CEO, Dario C. Altieri, M.D., and team have demonstrated the role of Parkin — a protein implicated in...
RGB _ RENOVARO _ LOGO _ with word mark.png
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
September 17, 2024 09:00 ET | Renovaro Inc
AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation...
RNAZ White background cropped.jpg
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
September 17, 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
factMR-logo.png
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR
September 17, 2024 06:00 ET | FACT.MR
Rockville, MD, Sept. 17, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global chemotherapy induced nausea and vomiting treatment...
image1 (1).png
Eisbach Bio Announces First Patient Dosed in Phase 1/2 Trial for EIS-12656, a First-In-Class Allosteric Inhibitor of ALC1 in Refractory Advanced Solid Tumors
September 16, 2024 07:00 ET | Eisbach Bio GmbH
The first patient has been dosed in Eisbach Bio’s Phase 1/2 MATCH clinical trial at MD Anderson assessing the ALC1 inhibitor EIS-12656 in solid tumors.
NOVARTIS logo.jpg
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
September 16, 2024 04:15 ET | Novartis Pharma AG
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1Results remain...
RGB _ RENOVARO _ LOGO _ with word mark.png
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
September 13, 2024 09:00 ET | Renovaro Inc
AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce...